We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Krystal Biotech Inc (KRYS) USD0.00001

Sell:$57.66 Buy:$57.75 Change: $1.29 (2.19%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
Change: $1.29 (2.19%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
Change: $1.29 (2.19%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Krystal Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of redosable gene therapies for patients living with debilitating diseases. It has developed a gene delivery platform that enables off-the-shelf treatments for serious dermatology and respiratory diseases. Its platform consists of an engineered viral vector derived from the herpes simplex virus type 1 (HSV-1) that it has optimized for local and repeat gene transfer to epithelial cells. Its product candidates in various stages of clinical and preclinical development include Vyjuvek for dystrophic epidermolysis bullosa (Dystrophic EB), KB105 for TGM1-deficient autosomal recessive congenital ichthyosis (ARCI), KB104 for Netherton Syndrome, KB407 for Cystic Fibrosis (CF), and KB408 for Alpha-1 antitrypsin deficiency (AATD). Its KB301 is for aesthetic skin conditions. Its subsidiary, Jeune Aesthetics, Inc, focuses on preclinical and clinical studies for aesthetic skin conditions.

Contact details

2100 Wharton St Ste 701
United States
+1 (412) 5865830

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.51 billion
Shares in issue:
25.64 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Krish Krishnan
    Chairman of the Board, President, Chief Executive Officer
  • Suma Krishnan
    Founder, Chief Operating Officer, Director, President - Research and Development
  • Bhushan Hardas
    President - Jeune, Inc
  • Kathryn Romano
    Chief Accounting Officer
  • Jing Marantz
    Chief Business Officer
  • Andy Orth
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.